This article is a correction to:
Multidisciplinary Tinnitus Research: Challenges and Future Directions From the Perspective of Early Stage Researchers
Jorge Piano Simoes1*†
Elza Daoud2*†
Maryam Shabbir3*†
Sana Amanat4
Kelly Assouly5,6,7
Roshni Biswas3,8
Chiara Casolani9,10,11
Albi Dode12
Falco Enzler2
Laure Jacquemin13,14
Mie Joergensen9,15Tori Kok16Nuwan Liyanage17,18Matheus Lourenco19,20
Punitkumar Makani21,22
Muntazir Mehdi23Anissa L. Ramadhani24,25
Constanze Riha26
Jose Lopez Santacruz21,22
Axel Schiller1
Stefan Schoisswohl1
Natalia Trpchevska27
Eleni Genitsaridi3,28*†- 1Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany
- 2Centre National de la Recherche Scientifique, Aix-Marseille University, Marseille, France
- 3Hearing Sciences, Mental Health and Clinical Neurosciences, School of Medicine, University of Nottingham, Nottingham, United Kingdom
- 4Otology & Neurotology Group CTS 495, Department of Genomic Medicine, GENYO - Centre for Genomics and Oncological Research Pfizer/University of Granada/Junta de Andalucía, PTS, Granada, Spain
- 5Department of Otorhinolaryngology and Head & Neck Surgery, University Medical Center Utrecht, Utrecht, Netherlands
- 6Department of Clinical and Experimental Neuroscience, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, Netherlands
- 7Cochlear Technology Centre, Mechelen, Belgium
- 8Laboratory of Lifestyle Epidemiology, Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
- 9Hearing Systems, Department of Health Technology, Technical University of Denmark, Lyngby, Denmark
- 10Oticon A/S, Smoerum, Denmark
- 11Interacoustics Research Unit, Lyngby, Denmark
- 12Institute of Databases and Information Systems, Ulm University, Ulm, Germany
- 13Department of Otorhinolaryngology Head and Neck Surgery, Antwerp University Hospital, Edegem, Belgium
- 14Department of Translational Neurosciences, Faculty of Medicine and Health Sciences, Antwerp University, Wilrijk, Belgium
- 15WS Audiology, Lynge, Denmark
- 16Ear Institute, University College London, London, United Kingdom
- 17University of Zurich, Zurich, Switzerland
- 18Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, Zurich, Switzerland
- 19Experimental Health Psychology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, Netherlands
- 20Health Psychology Research Group, Faculty of Psychology and Educational Sciences, University of Leuven, Leuven, Belgium
- 21Department of Otorhinolaryngology, Head and Neck Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
- 22Graduate School of Medical Sciences (Research School of Behavioral and Cognitive Neurosciences), University of Groningen, Groningen, Netherlands
- 23Institute of Distributed Systems, Ulm University, Ulm, Germany
- 24Radiological Sciences, Mental Health and Clinical Neurosciences, School of Medicine, University of Nottingham, Nottingham, United Kingdom
- 25Sir Peter Mansfield Imaging Centre, School of Medicine, University of Nottingham, Nottingham, United Kingdom
- 26Chair of Neuropsychology, Department of Psychology, University of Zurich, Zurich, Switzerland
- 27Department of Physiology and Pharmacology, Experimental Audiology Laboratory, Karolinska Institutet, Stockholm, Sweden
- 28Nottingham Biomedical Research Centre, National Institute for Health Research, Nottingham, United Kingdom
A Corrigendum on
Multidisciplinary Tinnitus Research: Challenges and Future Directions From the Perspective of Early Stage Researchers
by Simoes, J. P., Daoud, E., Shabbir, M., Amanat, S., Assouly, K., Biswas, R., et al. (2021). Front. Aging Neurosci. 13:647285. doi: 10.3389/fnagi.2021.647285
In the original article, there was an error. For the sentence “NMDA receptor antagonists (AM-101) have been discontinued in phase III for not meeting endpoints (van de Heyning et al., 2014)” there was a typographical error (phase III should have been phase II). In addition, it was brought to our attention that clinical trials for AM-101 are ongoing.
A correction has been made to section 6. Treatment Development, Subsection 6.4. Pharmacology-Based Interventions, paragraph 1. The corrected paragraph is below.
A wide variety of therapeutic drugs have been used to relieve tinnitus (Elgoyhen and Langguth, 2010). For acute tinnitus, a dose-dependent reduction in tinnitus intensity was observed with intravenous lidocaine (Trellakis et al., 2006). However, its use is controversial due to its short-lasting response, its potentially life threatening arrhythmogenic side effects, and the low bioavailability of its oral form (Israel et al., 1982; Trellakis et al., 2007; Gil-Gouveia and Goadsby, 2009). A potential goal of pharmacologic tinnitus research could be to identify the mechanism by which lidocaine interferes with tinnitus and mimic this effect using a drug with better tolerance that can be orally administered. For chronic tinnitus, the off-label use of medicines like betahistine (Hall et al., 2018d), anticonvulsants (Hoekstra et al., 2011), and glutamate receptor antagonists have shown little or no effect in clinical trials. Prescription of antidepressants and benzodiazepines is limited to tinnitus-associated comorbidities such as depression, insomnia and anxiety (Langguth et al., 2019). Moreover, three clinical research programs, in the last few years, were discontinued in phase II and III. AMPA antagonist selurampanel (BGG492) has not resulted in a new compound (Cederroth et al., 2018). NMDA receptor antagonists (AM-101) did not meet the primary endpoint of improving minimum masking level in acute tinnitus in a phase II clinical trial but showed improvement for tinnitus loudness, annoyance, sleep difficulties, and tinnitus impact in patients with tinnitus after noise trauma or otitis media (van de Heyning et al., 2014). Many other treatments decreasing tinnitus percept or targeting central auditory processing pathways are at a preclinical phase (Schilder et al., 2019). The modulator of voltage-gated potassium channels (Kv3.1) (AUT00063) was not effective in alleviating tinnitus symptoms (Hall et al., 2019b).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Cederroth, C. R., Dyhrfjeld-Johnsen, J., and Langguth, B. (2018). An update: emerging drugs for tinnitus. Expert Opin. Emerg. Drugs 23, 251?260. doi: 10.1080/14728214.2018.1555240
Elgoyhen, A. B., and Langguth, B. (2010). Pharmacological approaches to the treatment of tinnitus. Drug Discov. Today 15, 300?305. doi: 10.1016/j.drudis.2009.11.003
Gil-Gouveia, R., and Goadsby, P. (2009). Neuropsychiatric side-effects of lidocaine: examples from the treatment of headache and a review. Cephalalgia 29, 496?508. doi: 10.1111/j.1468-2982.2008.01800.x
Hall, D. A., Ray, J., Watson, J., Sharman, A., Hutchison, J., Harris, P., et al. (2019b). A balanced randomised placebo controlled blinded phase iia multi-centre study to investigate the efficacy and safety of aut00063 versus placebo in subjective tinnitus: the quiet-1 trial. Hear. Res. 377, 153?166. doi: 10.1016/j.heares.2019.03.018
Hall, D. A., Wegner, I., Smit, A. L., McFerran, D., and Stegeman, I. (2018d). Betahistine for tinnitus. Cochrane Database Syst. Rev. 2018:CD013093. doi: 10.1002/14651858.CD013093.pub2
Hoekstra, C. E., Rynja, S. P., van Zanten, G. A., and Rovers, M. M. (2011). Anticonvulsants for tinnitus. Cochrane Database Syst. Rev. 7:CD007960. doi: 10.1002/14651858.CD007960.pub2
Israel, J. M., Connelly, J. S., McTigue, S. T., Brummett, R. E., and Brown, J. (1982). Lidocaine in the treatment of tinnitus aurium: a double-blind study. Arch. Otolaryngol. 108, 471–473.
Langguth, B., Elgoyhen, A. B., and Cederroth, C. R. (2019). Therapeutic approaches to the treatment of tinnitus. Annu. Rev. Pharmacol. Toxicol. 59, 291?313. doi: 10.1146/annurev-pharmtox-010818-021556
Schilder, A. G., Su, M. P., Blackshaw, H., Lustig, L., Staecker, H., Lenarz, T., et al. (2019). Hearing protection, restoration, and regeneration: an overview of emerging therapeutics for inner ear and central hearing disorders. Otol. Neurotol. 40, 559?570. doi: 10.1097/MAO.0000000000002194
Trellakis, S., Benzenberg, D., Urban, B. W., and Friederich, P. (2006). Differential lidocaine sensitivity of human voltage-gated potassium channels relevant to the auditory system. Otol. Neurotol. 27, 117?123. doi: 10.1097/01.mao.0000186443.11832.8a
Trellakis, S., Lautermann, J., and Lehnerdt, G. (2007). Lidocaine: neurobiological targets and effects on the auditory system. Prog. Brain Res. 166, 303?322. doi: 10.1016/S0079-6123(07)66028-2
Keywords: tinnitus, review, heterogeneity, standardization, interdisciplinary collaborations, big data, treatment development
Citation: Simoes JP, Daoud E, Shabbir M, Amanat S, Assouly K, Biswas R, Casolani C, Dode A, Enzler F, Jacquemin L, Joergensen M, Kok T, Liyanage N, Lourenco M, Makani P, Mehdi M, Ramadhani AL, Riha C, Santacruz JL, Schiller A, Schoisswohl S, Trpchevska N and Genitsaridi E (2021) Corrigendum: Multidisciplinary Tinnitus Research: Challenges and Future Directions From the Perspective of Early Stage Researchers. Front. Aging Neurosci. 13:730758. doi: 10.3389/fnagi.2021.730758
Received: 25 June 2021; Accepted: 02 July 2021;
Published: 09 August 2021.
Edited and reviewed by: Daniel Ortuño-Sahagún, University of Guadalajara, Mexico
Copyright © 2021 Simoes, Daoud, Shabbir, Amanat, Assouly, Biswas, Casolani, Dode, Enzler, Jacquemin, Joergensen, Kok, Liyanage, Lourenco, Makani, Mehdi, Ramadhani, Riha, Santacruz, Schiller, Schoisswohl, Trpchevska and Genitsaridi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Eleni Genitsaridi, eleni.genitsaridi@nottingham.ac.uk; Jorge Piano Simoes, jorge.simoes@ukr.de; Maryam Shabbir, maryam.shabbir@nottingham.ac.uk; Elza Daoud, elzadaoud@gmail.com
†These authors have contributed equally to this work and share first and senior authorship